Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Welcome to OncLive On Air^®! I’m your host today, Chris Ryan.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Paul G. Richardson, MD, about the investigation of mezigdomide and dexamethasone in the treatment of patients with heavily pretreated relapsed/refractory multiple myeloma. Dr Richardson is a physician, clinical program leader, and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute as well as the RJ Corman Professor of Medicine at Harvard Medical School, both in Boston, Massachusetts.

Data from a phase 1/2 trial (NCT03374085) published in the New England Journal of Medicine demonstrated that the combination of mezigdomide and dexamethasone elicited an overall response rate (ORR) of 25% (95% CI, 16%-36%) among 77 patients with relapsed/refractory multiple myeloma treated in the study’s phase 1 dose-escalation cohort. Additionally, 101 patients treated in the phase 2 dose-escalation cohort achieved an ORR of 41% (95% CI, 31%-51%). Safety findings showed that the most common toxicities were primarily myelotoxic adverse effects.

In our exclusive interview, Dr Richardson walked through the background of mezigdomide, the design of the phase 1/2 study, key efficacy and safety findings with the regimen, and the implications of what this combination could mean for heavily pretreated patients with relapsed/refractory multiple myeloma.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air^®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air^® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.